Fidarestat is an aldose reductase inhibitor (IC50s: 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10, and V301L AKR1B10, respectively). It has the potential to treat diabetic disease.
AKR1B10-IN-1, a powerful AKR1B10 (Aldo-Keto Reductase 1B10) inhibitor, demonstrates an IC50 value of 3.5 nM. This compound effectively curtails the proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells.